Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07729605 | FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC(FIRBIT) | not yet recruiting | Phase 3 | 270 | Sun Yat-sen UniversityOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729618 | AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma(HCC-AI-SELECT) | not yet recruiting | N/A | 1,800 | Tongji HospitalOTHER | 1 | Jul 27, 2026 |
| clinicaltrials |
| NCT07118800 | Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old(NACRE-2) | not yet recruiting | Phase 3 | 160 | UNICANCEROTHER | 0 | Jul 24, 2026 | clinicaltrials |
| NCT07458113 | Sac-TMT for Active TNBC Brain Metastases(BERLIN) | not yet recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07723534 | Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers | not yet recruiting | Phase 2 | 32 | Midhun MallaOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07725796 | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC | not yet recruiting | Phase 1 | 30 | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07726342 | SMP-656 for HER2-Positive Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | Chengdu SciMount Pharmatech Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07606287 | Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital | not yet recruiting | N/A | 4,000 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07641855 | A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07703605 | AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors | not yet recruiting | — | 1,400 | Huashan HospitalOTHER | 0 | Jul 23, 2026 | clinicaltrials |
| NCT07721259 | A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden | not yet recruiting | Phase 2 | 60 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07723235 | Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial | not yet recruiting | N/A | 90 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07723781 | Structured Case-Finding for Pancreatic Ductal Adenocarcinoma in Swiss Primary Care: A Feasibility Study(PANCATCH-Pilot) | not yet recruiting | — | 50 | Saskia HendrichOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07168785 | [18F]-AraG PET Imaging in LA HNSCC | not yet recruiting | Early Phase 1 | 5 | Indiana UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07684066 | D-TECT: Pretreatment D-dimers and Disease Control in Advanced cSCC Treated With Cemiplimab(D-TECT) | not yet recruiting | — | 116 | Universitätsklinikum Hamburg-EppendorfOTHER | 2 | Jul 22, 2026 | clinicaltrials |
| NCT07720167 | Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07720921 | Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )(LUXUS0701) | not yet recruiting | Phase 2 | 20 | Peking University First HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07721103 | Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(Keystone006) | not yet recruiting | Phase 2 | 110 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07077083 | CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC(CAIX PET/CT) | not yet recruiting | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07241273 | SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer(SELECT-FR) | not yet recruiting | N/A | 128 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07690683 | Patients With Hepatocellular Carcinoma (HCC)(FORCE) | not yet recruiting | N/A | 52 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07714447 | Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 91 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07716046 | Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer(FACET) | not yet recruiting | Phase 2 | 240 | Fudan UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07716345 | Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer | not yet recruiting | — | 100 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07717450 | Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.(TAILORswitch) | not yet recruiting | Phase 3 | 370 | UNICANCEROTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07714070 | Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia(PKUPH-ORLPP-EC) | not yet recruiting | Phase 2 | 48 | Peking University People's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) | not yet recruiting | Phase 1 / Phase 2 | 90 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07715565 | Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial | not yet recruiting | Phase 2 | 66 | West China HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715734 | Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma(CONTRAC-2) | not yet recruiting | Phase 2 | 22 | Washington University School of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715747 | A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 128 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07709767 | Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 21 | Tang-Du HospitalOTHER | 0 | Jul 17, 2026 | clinicaltrials |
| NCT07711067 | A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer(MATTERS-2) | not yet recruiting | Phase 2 / Phase 3 | 95 | ElmediXINDUSTRY | 2 | Jul 17, 2026 | clinicaltrials |
| NCT07712094 | AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer | not yet recruiting | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064902 | Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07686926 | Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07693855 | Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors(THOR) | not yet recruiting | N/A | 69 | National Taiwan University HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07707661 | Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor(SRUS) | not yet recruiting | — | 350 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07709052 | Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)(B-PDAC) | not yet recruiting | — | 180 | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | not yet recruiting | Early Phase 1 | 6 | Royan InstituteOTHER_GOV | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709585 | Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients(BE-MASTER) | not yet recruiting | Phase 2 | 124 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT07653438 | In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy(PulmoPrint) | not yet recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer(MORALE-HN01) | not yet recruiting | Phase 1 / Phase 2 | 18 | Glycyx TherapeuticsINDUSTRY | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704203 | Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy | not yet recruiting | — | 150 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704216 | Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer | not yet recruiting | — | 150 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704645 | The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 180 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705919 | DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07691515 | Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma(RAINBOW) | not yet recruiting | Phase 3 | 140 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07699757 | HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion | not yet recruiting | Phase 1 | 258 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 27, 2026source: clinicaltrials